PURE Bioscience Restructures Leadership, Bets on Long-Term Operational Stability

NEW YORK, NY – November 19, 2025

PURE Bioscience, Inc. today announced a restructuring of its leadership team, appointing Jeff Kitchell as President and Dolana Blount as Vice President of Operations, effective immediately. Robert Bartlett will remain CEO, relinquishing his role as President. The move signals a strategic shift for the company, emphasizing operational execution and long-term stability, while navigating a challenging market for antimicrobial technologies.

Internal Promotions Signal Confidence in Existing Team

The appointments of Kitchell and Blount, both long-tenured employees with over two decades of experience at PURE Bioscience, represent a clear vote of confidence in the company’s existing team. Kitchell, previously Vice President of Operations, brings a deep understanding of the company's day-to-day functions and a proven track record of implementing new structures. Blount, who has held various roles since 1998, offers expertise in regulatory affairs, manufacturing oversight, and quality assurance.

“The decision to promote from within reflects our belief that we have the right people in place to drive our next phase of growth,” said one industry analyst familiar with the company’s strategy. “By placing experienced hands in key operational roles, PURE is signaling a commitment to stability and a focus on executing its existing business plan.”

The restructuring allows Bartlett to focus solely on his responsibilities as CEO, concentrating on strategic direction and overall growth initiatives. The separation of roles appears designed to streamline decision-making and enhance accountability.

Navigating a Competitive Antimicrobial Market

PURE Bioscience specializes in developing and commercializing its patented silver dihydrogen citrate (SDC) antimicrobial technology, primarily targeting the food and beverage industry. The company’s SDC technology aims to provide a non-toxic solution for controlling harmful bacteria and pathogens. However, the antimicrobial market is becoming increasingly competitive, with a growing number of players offering innovative solutions.

Recent research indicates the global antimicrobial coatings market is projected to reach $3.8 billion by 2030, driven by increasing concerns about food safety, healthcare-associated infections, and the spread of antibiotic-resistant bacteria. However, competition is fierce, with established players like DuPont, BASF, and AkzoNobel, as well as emerging startups, vying for market share.

“The key to success in this market is differentiation,” explained one food safety consultant. “Companies need to demonstrate that their technology offers a unique advantage in terms of efficacy, safety, cost-effectiveness, and sustainability.”

PURE’s SDC technology boasts a unique non-toxic profile, positioning it as a potential alternative to traditional antimicrobial agents. However, the company must continue to invest in research and development to maintain its competitive edge and expand its applications.

Financial Performance and Growth Prospects

PURE Bioscience recently reported fiscal year 2025 net product sales of $2.198 million, an increase from $1.955 million in the previous year. While revenue has grown, the company continues to operate at a loss, reporting a net loss of $2.4 million for the year. The company attributes the loss to investments in research and development, as well as the costs associated with commercializing its SDC technology.

“While the financial performance is still a concern, we are encouraged by the progress we have made in reducing our losses,” stated a company spokesperson. “We believe that our SDC technology has the potential to become a leading solution in the food and beverage industry, and we are confident that we can achieve profitability in the coming years.”

Analysts remain cautious, highlighting the company’s reliance on a single technology and the challenges associated with scaling up production and distribution. “PURE needs to demonstrate consistent revenue growth and a clear path to profitability to attract investors and sustain its business,” said one financial analyst. “The leadership restructuring is a positive step, but it’s not enough on its own.”

The company’s stock (OTCQB: PURE) is currently trading at around $0.13 per share, reflecting the market’s skepticism. However, some investors believe that the stock is undervalued, given the potential of its SDC technology and the growing demand for antimicrobial solutions.

Recent financial analysis suggests that PURE faces significant financial instability and operates with declining revenues. One report emphasizes the negative P/E ratio, suggesting the company requires severe operational improvements for future growth.

Despite these challenges, PURE Bioscience remains committed to its mission of providing safer and more sustainable solutions for controlling harmful bacteria and pathogens. The leadership restructuring is a testament to this commitment, and the company is confident that it can achieve its long-term growth objectives.